Enterococcus faecalis

Enterococcus faecalis
United States Department of Agriculture · Public domain · source
Name	Enterococcus faecalis
Domain	Bacteria
Phylum	Firmicutes
Classis	Bacilli
Ordo	Lactobacillales
Familia	Enterococcaceae
Genus	Enterococcus
Species	E. faecalis

Enterococcus faecalis Enterococcus faecalis is a Gram-positive, facultatively anaerobic, lactic acid bacterium historically isolated from human and animal gastrointestinal tracts. It is recognized for its role in nosocomial infections, biofilm formation on medical devices, and remarkable capacity to acquire antibiotic resistance through horizontal gene transfer. Clinical microbiology, infection control, and molecular epidemiology communities monitor E. faecalis alongside other opportunistic pathogens because of its associations with bloodstream infections, endocarditis, and urinary tract infections.

Taxonomy and Morphology

E. faecalis is classified within the phylum Firmicutes, class Bacilli, order Lactobacillales, family Enterococcaceae, and genus Enterococcus, reflecting historical work in bacterial systematics by researchers associated with institutions such as the Pasteur Institute and the British Society for Antimicrobial Chemotherapy. Morphologically, cells are spherical to ovoid cocci appearing in pairs and short chains when observed by light microscopy used in clinical laboratories at hospitals like Massachusetts General Hospital and St. Thomas' Hospital. Gram staining protocols developed in the 19th century at University College London and microscopy techniques refined at the Royal Society remain central to initial identification, while phenotypic tests influenced by early studies from the Rockefeller Institute complement genomic approaches developed at the Broad Institute and Max Planck Institute.

Ecology and Natural Habitat

E. faecalis is part of the commensal microbiota of the human gastrointestinal tract with ecological studies referencing cohorts from Johns Hopkins University, University of Oxford, and Harvard Medical School. Environmental reservoirs include soil and aquatic habitats impacted by agricultural runoff studied by researchers at Wageningen University, University of California, Davis, and Kyoto University. Transmission dynamics have been examined in hospital settings such as Johns Hopkins Hospital and Mayo Clinic, and in community outbreaks traced by public health agencies like the Centers for Disease Control and Prevention and Public Health England. Comparative ecology studies often involve collaborations with the Wellcome Sanger Institute and Institut Pasteur.

Pathogenicity and Clinical Significance

E. faecalis causes a spectrum of infections including infective endocarditis treated in cardiac centers like Cleveland Clinic, urinary tract infections managed by clinics at Mount Sinai Hospital, intra-abdominal infections, and catheter-associated bloodstream infections monitored by the World Health Organization and the European Centre for Disease Prevention and Control. Clinical case series published by authors affiliated with University College London Hospitals, Stanford Health Care, and Johns Hopkins report associations with prosthetic valve endocarditis and surgical site infections. Outbreak investigations involving E. faecalis have been reported by Santé publique France and the Robert Koch Institute, emphasizing its relevance to hospital epidemiology programs at institutions such as UCSF Medical Center.

Antibiotic Resistance and Mechanisms

E. faecalis exhibits intrinsic and acquired resistance to multiple antibiotic classes, with clinically important mechanisms documented by research groups at the National Institutes of Health, Institut Pasteur, and Karolinska Institutet. Resistance phenotypes include high-level aminoglycoside resistance, beta-lactam tolerance, and vancomycin resistance mediated by van gene clusters characterized by teams at Oxford University and the University of Cambridge. Mobile genetic elements such as plasmids and transposons studied at Rockefeller University and the Pasteur Institute facilitate horizontal gene transfer observed in surveillance networks coordinated by the European Antimicrobial Resistance Surveillance Network and the CDC’s Antibiotic Resistance Laboratory Network.

Virulence Factors and Molecular Biology

Key virulence determinants include aggregation substance, cytolysin, gelatinase, surface adhesins, and capsule polysaccharides; molecular characterization of these factors has been led by laboratories at the University of Pennsylvania, University of Toronto, and McMaster University. Biofilm formation on indwelling devices has been modeled in research from the Karolinska Institutet and the University of Melbourne, while regulatory networks and quorum sensing pathways were elucidated by investigators at MIT and Rockefeller University. Genomic studies from the Broad Institute, Wellcome Sanger Institute, and EMBL have cataloged pathogenicity islands and comparative genomics across clinical and environmental isolates.

Diagnosis and Laboratory Identification

Clinical laboratories at institutions like Mayo Clinic, Cleveland Clinic, and Imperial College London use culture on selective media, bile esculin testing, PYR test, and antibiotic susceptibility testing guided by standards from the Clinical and Laboratory Standards Institute and the European Committee on Antimicrobial Susceptibility Testing. MALDI-TOF mass spectrometry platforms developed by Bruker and bioMérieux are widely adopted for rapid species-level identification in centers such as Johns Hopkins and UCLA Medical Center. Molecular diagnostics including PCR assays and whole-genome sequencing employed by the Wellcome Sanger Institute and the Broad Institute support outbreak investigation and resistance gene detection.

Prevention, Treatment, and Control

Prevention strategies emphasize hand hygiene promoted by the World Health Organization and targeted infection control practices implemented in hospitals like Singapore General Hospital and Mount Sinai, including contact precautions and environmental decontamination protocols based on guidance from Public Health England. Treatment options are informed by susceptibility testing and may include ampicillin, aminoglycoside synergy, linezolid, daptomycin, and agents used under stewardship programs run by institutions such as Johns Hopkins Antimicrobial Stewardship Program and the CDC. Research into vaccines and novel antimicrobials is ongoing at pharmaceutical companies like Pfizer and academic centers including University of Oxford, University of California, San Diego, and Institut Pasteur.

Category:Bacteria